BARACLUDE

LOE Approaching

entecavir

NDAORALTABLETPriority Review
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
49

Mechanism of Action

12.1 Mechanism of Action Entecavir is an antiviral drug against hepatitis B virus [see ]. 12.3 Pharmacokinetics The single- and multiple-dose pharmacokinetics of entecavir were evaluated in healthy subjects and subjects with chronic hepatitis B virus infection. Absorption Following oral…

Clinical Trials (5)

NCT05494528N/AUnknown

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Started May 2021
NCT04180150Phase 2Unknown

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

Started Nov 2019
NCT04157257Phase 2Unknown

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy

Started Jul 2019
NCT03847246N/ACompleted

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

Started Dec 2018
NCT03577171Phase 2Completed

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Started Jun 2018